Segment Information - Schedule of Reconciles Segment Direct Profit or Loss (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Segment Reporting Information [Line Items]
Total research and development	$ 6,528	$ 3,182	$ 15,720	$ 5,608
Total general and administrative	3,649	1,880	11,578	4,121
Loss from operations	(10,177)	(5,062)	(27,298)	(9,729)
QTORIN Rapamycin for Microcystic LM [Member]
Segment Reporting Information [Line Items]
Total research and development	1,103	651	3,492	1,078
QTORIN Rapamycin for Microcystic LM - Government Grant Income [Member]
Segment Reporting Information [Line Items]
Total research and development	(53)	(14)	(392)	(14)
QTORIN Rapamycin For Cutaneous VM [Member]
Segment Reporting Information [Line Items]
Total research and development	827	73	1,527	73
QTORIN Rapamycin CMC [Member]
Segment Reporting Information [Line Items]
Total research and development	2,265	847	4,554	1,000
Salaries and Stock-based Compensation [Member]
Segment Reporting Information [Line Items]
Total research and development	1,658	1,021	4,481	2,373
Total general and administrative	2,151	682	5,348	1,439
Consultants [Member]
Segment Reporting Information [Line Items]
Total research and development	414	355	1,046	705
Total general and administrative	587	908	2,497	2,186
Other [Member]
Segment Reporting Information [Line Items]
Total research and development	314	249	1,012	393
Total general and administrative	$ 911	$ 290	$ 3,733	$ 496